Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Proton Rahman

Showing results (171-180 of 260) with videos related to

Pageof 26
Sort By:
The Journal of Rheumatology|April 17, 2009
IL-23R polymorphisms in patients with ankylosing spondylitis in KoreaIl-Hoon Sung, Tae-Hwan Kim, So-Young Bang, et al.
The Lancet. Rheumatology|January 30, 2024
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 studyLaura C Coates, William Tillett, Maria-Antonietta D'Agostino, et al.
Annals of the Rheumatic Diseases|March 19, 2018
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 studyPhilip Mease, Désirée van der Heijde, Robert Landewé, et al.
RMD Open|February 24, 2023
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritisAlice B Gottlieb, Iain B McInnes, Proton Rahman, et al.
Arthritis and Rheumatism|December 1, 2007
Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled studyRobert G W Lambert, David Salonen, Proton Rahman, et al.
Annals of the Rheumatic Diseases|January 19, 2011
High resolution mapping in the major histocompatibility complex region identifies multiple independent novel loci for psoriatic arthritisProton Rahman, Nicole M Roslin, Fawnda J Pellett, et al.
Annals of the Rheumatic Diseases|May 14, 2021
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb studyPhilip J Mease, Saima Chohan, Ferran J Garcia Fructuoso, et al.
Plos One|August 15, 2014
Bone morphogenetic protein 6 polymorphisms are associated with radiographic progression in ankylosing spondylitisYoung Bin Joo, So-Young Bang, Tae-Hwan Kim, et al.
RMD Open|July 31, 2021
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 studyPhilip J Mease, Robert Landewé, Proton Rahman, et al.
Clinical Rheumatology|October 3, 2023
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatmentPhilip J Mease, Alice B Gottlieb, Alexis Ogdie, et al.
Pageof 26

Showing results (171-180 of 260) with videos related to

Sort By:
Pageof 26
The Journal of Rheumatology|April 17, 2009
IL-23R polymorphisms in patients with ankylosing spondylitis in KoreaIl-Hoon Sung, Tae-Hwan Kim, So-Young Bang, et al.
The Lancet. Rheumatology|January 30, 2024
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 studyLaura C Coates, William Tillett, Maria-Antonietta D'Agostino, et al.
Annals of the Rheumatic Diseases|March 19, 2018
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 studyPhilip Mease, Désirée van der Heijde, Robert Landewé, et al.
RMD Open|February 24, 2023
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritisAlice B Gottlieb, Iain B McInnes, Proton Rahman, et al.
Arthritis and Rheumatism|December 1, 2007
Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled studyRobert G W Lambert, David Salonen, Proton Rahman, et al.
Annals of the Rheumatic Diseases|January 19, 2011
High resolution mapping in the major histocompatibility complex region identifies multiple independent novel loci for psoriatic arthritisProton Rahman, Nicole M Roslin, Fawnda J Pellett, et al.
Annals of the Rheumatic Diseases|May 14, 2021
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb studyPhilip J Mease, Saima Chohan, Ferran J Garcia Fructuoso, et al.
Plos One|August 15, 2014
Bone morphogenetic protein 6 polymorphisms are associated with radiographic progression in ankylosing spondylitisYoung Bin Joo, So-Young Bang, Tae-Hwan Kim, et al.
RMD Open|July 31, 2021
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 studyPhilip J Mease, Robert Landewé, Proton Rahman, et al.
Clinical Rheumatology|October 3, 2023
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatmentPhilip J Mease, Alice B Gottlieb, Alexis Ogdie, et al.
Pageof 26